Unscheduled diagnosed treatment backlog
Diagnosed, unscheduled treatment
$218,400
$176,900 vs. same week last quarter
- Patients with open plans
- 311
- Plans > $2,000
- 44 · $131,200
- Case acceptance (30d)
- 61% (prior 67%)
What changed. Diagnosed treatment is accumulating faster than it is being scheduled, mostly in higher-value plans.
Why it might have changed. Possible cause: no financing option presented. 31 of 44 large plans have no financing or phasing note.
Recommended this week. Run a treatment coordinator call list for the 44 plans over $2,000 with phased options and financing, tracked in the PMS.
Suggested owner: Treatment Coordinator · Due 2026-10-03
Projected revenue (est.)
$47,200/yr
Collectible cash (est.)
$45,312/yr
EBITDA impact (est.)
$28,093/yr
Measured result
Baseline $61 captured 2026-09-14Diagnosed, unscheduled treatment: $61 → $63 (not improved)
Measured movement is shown separately from estimated opportunity. Improvement coincides with the action; Pento does not claim the action caused it.
- — Script approved by Dr. Patel.